Skip to main content

Journal Club

Tumor/Skull Base

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

J Clin Oncol | 2011

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1200/JCO.2010.30.1655

PMID

21041710

PICO

Population

Patients with 1-3 brain metastases from solid tumors (excluding small-cell lung cancer), WHO PS 0-2, stable systemic disease or asymptomatic primary.

Intervention

Adjuvant whole-brain radiotherapy (WBRT; 30 Gy in 10 fractions) after complete surgery or radiosurgery.

Comparator

Observation after complete surgery or radiosurgery.

Outcomes

Time to WHO PS deterioration >2 (primary), overall survival, intracranial relapse rates, neurologic death, salvage therapy use.

Design

Type

Phase III randomized controlled trial

Randomized

Yes

Multicenter

Yes

Blinded

Not applicable: open-label trial

Follow-up

Not specified in excerpt

Primary endpoint

Time to WHO performance status deterioration to >2

Secondary endpoints

  • Overall survival
  • Intracranial relapse rates at initial and new sites
  • Neurologic death
  • Salvage therapy frequency

Practice impact

What this means

This EORTC phase III trial randomized 359 patients with 1-3 brain metastases to adjuvant WBRT or observation after surgery/radiosurgery. WBRT reduced 2-year intracranial relapses (e.g., surgery initial sites: 59% to 27%) and neurologic deaths (44% to 28%) but did not improve time to functional deterioration (10.0 vs 9.5 months, P=0.71) or overall survival (10.7 vs 10.9 months, P=0.89). Omission of adjuvant WBRT is reasonable when prioritizing quality of life over relapse prevention.

Bottom line

Adjuvant WBRT after surgery or radiosurgery reduces intracranial relapses and neurologic deaths but does not improve functional independence or overall survival.

Strength of evidence

high

Recommendation

consider change

Why it matters

  • Phase III RCT with 359 patients.
  • Primary endpoint (functional independence) negative despite reduced relapses.
  • Supports omission of adjuvant WBRT when preserving neurocognition is prioritized.

What would change my mind

  • Trial showing WBRT improves neurocognitive outcomes with modern techniques.
  • Subgroup analysis identifying patients who benefit from WBRT (e.g., specific histologies).
  • Long-term data demonstrating survival benefit in molecularly selected cohorts.

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Low risk: randomized, multicenter design with clear allocation (199 radiosurgery, 160 surgery).

Confounding

Balanced by randomization; stratified by treatment modality (surgery vs radiosurgery).

Missing data

Not addressed in excerpt; 359 patients randomized.

Multiplicity

Multiple secondary endpoints reported without adjustment; primary endpoint negative.

Notes

  • Open-label may influence salvage therapy decisions.
  • Excludes small-cell lung cancer.

Stats check

NNT

Not applicable: no significant benefit in primary functional endpoint

Effect sizes

  • Median time to WHO PS >2: 10.0 months (OBS) vs 9.5 months (WBRT); HR not provided, P=0.71
  • Median overall survival: 10.7 months (OBS) vs 10.9 months (WBRT); P=0.89

Absolute effects

  • 2-year relapse at initial sites after surgery: 59% (OBS) vs 27% (WBRT); P<0.001
  • 2-year relapse at new sites after radiosurgery: 48% (OBS) vs 33% (WBRT); P=0.023
  • Intracranial progression death: 44% (OBS) vs 28% (WBRT)

Concerns

  • No hazard ratio or confidence interval for primary endpoint time-to-event.
  • Multiple comparisons for relapse endpoints without multiplicity adjustment.

External validity

Who it applies to

Neurosurgery/radiation oncology patients with 1-3 brain metastases from solid tumors (non-small-cell), good performance status, controlled systemic disease.

Who it does not

Patients with small-cell lung cancer, >3 metastases, poor performance status (WHO PS >2), or uncontrolled systemic disease.

Generalizability notes

  • Multicenter European trial enhances generalizability.
  • Modern radiosurgery techniques may yield different local control rates.

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 1 Methods

quote

Patients with one to three brain metastases... were treated with complete surgery or radiosurgery and randomly assigned to adjuvant WBRT or observation.

claim_id

stats_check.effect_sizes

locator

p. 1 Results

quote

The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after WBRT (P = .71).

claim_id

practice_impact.bottom_line

locator

p. 1 Results

quote

After radiosurgery or surgery of a limited number of brain metastases, adjuvant WBRT reduces intracranial relapses and neurologic deaths but fails to improve the duration of functional independence and overall survival.

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years